AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast

by Barry101 | Mar 27, 2023 | Press Release, Uncategorized

OCALA, Fla., March 27, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...

AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

by Barry101 | Mar 16, 2023 | Press Release, Uncategorized

Growing body of data supports Ampligen’s potential as both a prophylactic and an early-onset therapy against human Ebola virus disease outbreaksOCALA, Fla., March 16, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...

AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease

by Barry101 | Mar 8, 2023 | Press Release, Uncategorized

OCALA, Fla., March 08, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...

AIM ImmunoTech Issues Letter to Stockholders

by Barry101 | Mar 6, 2023 | Press Release, Uncategorized

Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with the investment and scientific communities Poised to achieve multiple clinical and regulatory...

AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients

by Barry101 | Feb 28, 2023 | Press Release, Uncategorized

Ongoing efforts to open additional clinical sites for recruitment at premier cancer centers across the U.S. and Europe are in progress to facilitate patient enrollment and dosingOCALA, Fla., Feb. 28, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM)...

AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”

by Barry101 | Feb 17, 2023 | Press Release, Uncategorized

OCALA, Fla., Feb. 17, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...